Skip to Content
Menu
About
Science
EDO Platform
Scientific Publications
Pipeline
Overview
Clinical Trials
Expanded Access Policy
Community
Careers
Investors
News
Contact
The FREEDOM-DM1 clinical trial demonstrated strong splicing correction with single doses of PGN-EDODM1, with an acceptable safety profile
Post navigation
Previous:
FREEDOM-DM1: Final Results from a Phase 1, Placebo-controlled SAD Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1)
Next:
Analysis of Individual Patient Mis-Splicing Data from PGN-EDODM1, an Investigational Therapy for Myotonic Dystrophy Type 1 (DM1)
